According to the research report, the US clinical trials market size is expected to touch USD 39.62 Billion by 2032, from USD 24.61 Billion in 2022, growing with a significant CAGR of 4.88% from 2022 to 2032.
The US clinical trials market report offers
a comprehensive study of the current state expected at the major drivers,
market strategies, and key vendors’ growth. The report presents energetic visions
to conclude and study the market size, market hopes, and competitive
surroundings. The research also focuses on the important achievements of the
market, research & development, and regional growth of the leading
competitors operating in the market. The current trends of the global US
clinical trials market in conjunction with the geographical landscape of this
vertical have also been included in this report.
The report offers intricate dynamics about
different aspects of the global US clinical trials market, which aids companies
operating in the market in making strategic development decisions. The study
also elaborates on significant changes that are highly anticipated to configure
growth of the global US clinical trials market during the forecast period. It
also includes a key indicator assessment that highlights growth prospects of this
market and estimates statistics related to growth of the market in terms of
value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/2480
| Report Coverage | Details |
| Market Size in 2022 | USD 24.61 Billion |
| Market Size by 2032 | USD 39.62 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 4.88% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Phase, By Study Design, By Indication |
This study covers a detailed segmentation
of the global US clinical trials market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global US clinical trials market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- Parexel International Corp.
- Charles River Laboratory
- PRA Health Sciences
- Wuxi AppTec
- Eli Lilly and Company
- Novo Nordisk A/S
- Clinipace
- Omnicare
- Kendle
- Chiltern
Market Segmentation
- Phase I
- Phase II
- Phase III
- Phase IV
By Study Design
- Interventional
- Observational
By Indication
- Oncology
- Autoimmune
- Pain Management
- CNS Conditions
- Obesity
- Cardiovascular
- Diabetes
Research Methodology
The research methodology adopted by
analysts for compiling the global US clinical trials market report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary
understanding of the global US clinical trials market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on US Clinical Trials Market
5.1. COVID-19 Landscape: US Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. US Clinical Trials Market, By Phase
8.1. US Clinical Trials Market, by Phase, 2023-2032
8.1.1 Phase I
8.1.1.1. Market Revenue and Forecast (2023-2032)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2023-2032)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2023-2032)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2023-2032)
Chapter 9. US Clinical Trials Market, By Study Design
9.1. US Clinical Trials Market, by Study Design, 2023-2032
9.1.1. Interventional
9.1.1.1. Market Revenue and Forecast (2023-2032)
9.1.2. Observational
9.1.2.1. Market Revenue and Forecast (2023-2032)
Chapter 10. US Clinical Trials Market, By Indication
10.1. US Clinical Trials Market, by Indication, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2023-2032)
10.1.2. Autoimmune
10.1.2.1. Market Revenue and Forecast (2023-2032)
10.1.3. Pain Management
10.1.3.1. Market Revenue and Forecast (2023-2032)
10.1.4. CNS Conditions
10.1.4.1. Market Revenue and Forecast (2023-2032)
10.1.5. Obesity
10.1.5.1. Market Revenue and Forecast (2023-2032)
10.1.6. Cardiovascular
10.1.6.1. Market Revenue and Forecast (2023-2032)
10.1.7. Diabetes
10.1.7.1. Market Revenue and Forecast (2023-2032)
Chapter 11. Global US Clinical Trials Market, Regional Estimates and Trend Forecast
11.1. U.S.
11.1.1. Market Revenue and Forecast, by Phase (2023-2032)
11.1.2. Market Revenue and Forecast, by Study Design (2023-2032)
11.1.3. Market Revenue and Forecast, by Indication (2023-2032)
Chapter 12. Company Profiles
12.1. Parexel International Corp.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Charles River Laboratory
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. PRA Health Sciences
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Wuxi AppTec
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Eli Lilly and Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novo Nordisk A/S
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Clinipace
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Omnicare
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Kendle
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Chiltern
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments